Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

immunization

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Mix-and-match COVID-19 vaccines may be more effective

A small study shows a booster shot of J&J’s vaccine six months after a primary course of the Pfizer/BioNTech vaccine may offer more protection

- PMLiVE

Keytruda gains eighth FDA approval this year

Merck’s megablockbuster Keytruda has returned to its roots with a new indication in melanoma, the therapy area where it was first approved seven years ago

- PMLiVE

Are you innovating on purpose?

By Martin Callaghan, Director of Innovation, Oxford PharmaGenesis

Climbing my own Lucid Ladder

Transforming lives. That’s what Lucid is all about. I knew that even before I stepped through the fabled door of ‘Towers’ on a chilly January morning in 2019. It’s why...

Lucid Group Communications Limited

- PMLiVE

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed

- PMLiVE

Lilly’s combination antibody expanded to children under 12

The FDA has expanded the emergency use for bamlanivimab with etesevimab for the treatment of and post-exposure prophylaxis against COVID-19 in high-risk children aged under 12

- PMLiVE

Working with purpose and putting talent development at the heart of operations

Margot Hannah is chief executive of OPEN Health Communications

A Lucid Thirsty Thursday D&I Special

Last week’s ‘Thirsty Thursday’ session was organised by the Lucid Group D&I Committee, whose goal is to foster a culture where diversity and inclusivity are embedded and practised within all...

Lucid Group Communications Limited

- PMLiVE

Diversity in clinical trials: looking back at our 2021 blogs

In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021

Innovative Trials

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

- PMLiVE

Annual COVID-19 jabs likely, says Pfizer head

Pfizer CEO predicts annual jabs will be needed to maintain a ‘very high level of protection’ against COVID-19 and emphasises the need to vaccinate children

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links